Get the Stockscreener App
141.25
0.41%
-0.58
Neurocrine Biosciences Inc stock is traded at $141.25, with a volume of 1.19M.
It is down -0.41% in the last 24 hours and down -1.91% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$141.83
Open:
$142.02
24h Volume:
1.19M
Relative Volume:
1.27
Market Cap:
$14.08B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
47.88
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-1.61%
1M Performance:
-1.91%
6M Performance:
+17.53%
1Y Performance:
+12.42%
1-Day Range:
$139.27
$143.50
1-Week Range:
$137.02
$145.08
52-Week Range:
$84.23
$157.67
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
141.25 | 14.14B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
122.87 | 53.79B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.22 | 45.18B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.67 | 43.95B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.77 | 27.78B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
477.20 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Extends Eiry W. Roberts’ Employment Term - TipRanks
Neurocrine review highlights key differences between tardive dyskinesia drugs - Indian Pharma Post
Distinctions Between VMAT2 Inhibitors Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments By Investing.com - Investing.com Canada
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Neurocrine Biosciences Inc Stock Analysis and ForecastEarnings Forecast Updates & High Yield Investment Portfolio - earlytimes.in
A Look at Neurocrine Biosciences (NBIX) Valuation After Setback in Depression Drug Trial - simplywall.st
What analysts say about Neurocrine Biosciences Inc stockMarket Depth Overview & Small Budget Big Profits - earlytimes.in
Asia Deal Watch: GSK To Collaborate With LTZ On Myeloid Cell Engagers - Citeline News & Insights
Is Neurocrine Biosciences Inc. (NB3) stock a safe buy pre earningsProfit Target & AI Based Trade Execution Alerts - newser.com
Neurocrine publishes review highlighting differences between tardive dyskinesia treatments - Investing.com
Neurocrine study highlights differences between tardive dyskinesia drugs - StreetInsider
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules - PR Newswire
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusPrice Action & AI Forecasted Entry/Exit Points - newser.com
How Neurocrine Biosciences Inc. stock reacts to bond yieldsFed Meeting & Weekly Momentum Picks - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidityPortfolio Performance Summary & AI Driven Price Forecasts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfoliosWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investorsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Can Neurocrine Biosciences Inc. stock weather global recessionJuly 2025 Short Interest & Smart Money Movement Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growth2025 Earnings Surprises & Technical Pattern Recognition Alerts - newser.com
Measuring Neurocrine Biosciences Inc.’s beta against major indicesJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
How to build a dashboard for Neurocrine Biosciences Inc. stockJuly 2025 Analyst Calls & Verified Stock Trade Ideas - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
How Neurocrine Biosciences Inc. stock responds to policy changes2025 Institutional Moves & Fast Exit Strategy with Risk Control - newser.com
A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further - Seeking Alpha
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com
Responsive Playbooks and the NBIX Inflection - news.stocktradersdaily.com
Neurocrine at Jefferies Conference: Growth and Strategic Plans - Investing.com
Neurocrine Biosciences (Nasdaq: NBIX) Reports Positive Phase 2 Osavampator MDD Data - Stock Titan
Is Neurocrine Biosciences Inc. stock trading near support levelsJuly 2025 Movers & High Accuracy Swing Entry Alerts - newser.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):